IGI Logo

Weak quarter; near-term outlook remains challenging

* Jyothy Laboratories (JYL) reported 3% YoY sales growth (miss) in 1QFY27, while volume growth was flat (est. 7%, 11% in 4QFY26). The Pril and FA agreement with Henkel has discontinued, effective from 31st May’26. ExPril and FA, value/volume growth stood at 8%/5%. Fabric Care remained the key growth driver, with 14% value and 10% volume growth, led by liquid detergents and powders. Home Care declined 9% YoY, but grew 2% ex-Pril. The newly launched Exo bio-enzyme franchise saw an encouraging initial response. Personal Care was flat YoY, impacted by 9–10% price hikes and supply chain disruptions, with recovery expected from 2QFY27.

* Gross margin contracted sharply by 950bp YoY to 38.5% (est. 46.0%; 45.2% in 4QFY26), impacted by elevated crude-linked raw material and weak competitive positioning. Around 90% of JYL’s business is linked to crude oil. The company has taken 4-4.5% cumulative price hikes, with ~3% already flowed in 1QFY27 and the balance expected in 2QFY27; however, pricing remains calibrated, given the intense competition and consumer affordability. EBITDA margin contracted 820bp YoY to 8.4% (est. 14.4%), with management expecting margin recovery to be gradual as high-cost inventory continues to flow through in 2QFY27. We model 12.4% and 15.4% EBITDA margin for FY27 and FY28.

* We remain cautious on JYL’s near-term outlook, with elevated competitive intensity from category leaders likely to constrain both growth and margin. This, coupled with sharp inflation in crude and its derivatives, is expected to further pressure the company’s performance. We have been cautious on JYL’s margin recovery amid competition and believe the recovery appears increasingly vulnerable in the current highcost inflationary environment. We reiterate our Neutral rating on the stock with a TP of INR210 (premised on 20x Mar’28E P/E).

Highlights from the management commentary

* Excluding Pril, revenue grew 8% YoY in value terms and 5% YoY in volume terms in 1QFY27. Management is targeting double-digit revenue growth in FY27, excluding the Pril business, with high-single-digit volume growth and 3–4% pricing expected to support growth.

* The company has taken around 4–4.5% cumulative price increases, of which around 3% has already flowed through in 1QFY27, while the balance is expected to reflect in 2QFY27.

* Around 90% of the company's business is linked to crude oil prices, making JYL more exposed to crude-linked inflation compared with several peers. Raw material costs increased by around 30–35%.

* Household insecticides were impacted by the extended summer and delayed rainfall during the quarter. The company launched Maxo incense sticks in July, targeting the growing concern around unsafe and unapproved local agarbattis.

Valuation and view

* We cut our EPS estimates by 18% for FY27 and 3% for FY28, primarily due to the margin miss resulting from higher RM prices.

* We remain cautious on JYL’s near-term outlook, with elevated competitive intensity from category leaders likely to constrain both growth and margin. This, coupled with sharp inflation in crude and its derivatives, is expected to further pressure the company’s performance. We have been cautious on JYL’s margin recovery amid competition and believe recovery appears further delayed in the current high-cost inflationary environment.

* We reiterate our Neutral rating on the stock with a TP of INR210 (premised on 20x Mar’28E P/E).

For More Research Reports : Click Here 

For More Motilal Oswal Securities Ltd Disclaimer
http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH000000412